Development and application of monoclonal antibodies against avian influenza virus nucleoprotein.

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Abstract Text:

Ming Yang,Yohannes Berhane,Tim Salo,Mingyi Li,Kate Hole,Alfonso Clavijo,Ming Yang,Yohannes Berhane,Tim Salo,Mingyi Li,Kate Hole,Alfonso Clavijo,

Rapid and accurate diagnosis of avian influenza (AI) infection is important for an understanding epidemiology. In order to develop rapid tests for AI antigen and antibody detection, two monoclonal antibodies (mAbs) against influenza nucleoprotein (NP) were produced. These mAbs are designated as F26-9 and F28-73 and able to recognize whole AI virus particles as well as the recombinant NP. Both of the mAbs were tested in a slot blot for their reactivity against 15 subtypes of influenza virus; F28-73 reacted with all tested 15 subtypes, while F26-9 failed to react with H13N6 and H15N8. The mAb binding epitopes were identified using truncated NP recombinant proteins and peptide array techniques. The mAb F26-9 reacted with NP-full, NP-1 (638bp), NP-2 (315bp), NP-4 (488bp), and NP-5 (400bp) in the Western blot. The peptide array results demonstrated that the mAb F26-9 reacted with NP peptides 15-17 corresponding to amino acids 71-96. The mAb F28-73 recognized the NP-full, -1 and -4 fragments, but failed bind to NP-2, -3, -5, and any peptides. This antibody-binding site is expected to be contained within 1-162 amino acids of AI NP, although the exact binding epitope could not be determined. The two mAbs showed reactivity with AI antigen in immunofluorescence, immunohistochemistry and immune plaque assays. Immune response of AI infected animals was determined using the mAb F28-73 in a cELISA. All tested chickens were positive at 11 days post-infection and remained positive until the end of the experiment on day 28 (>50% inhibition). The two mAbs with different specificities are appropriate for developing various tests for diagnosis of AI infection.

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Publishing Authors By Initials

M Yang,Y Berhane,T Salo,M Li,K Hole,A Clavijo,M Yang,Y Berhane,T Salo,M Li,K Hole,A Clavijo,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of virological methods

VOLUME: 147

Page Numbers: 265-74

Journal Abbreviation: J. Virol. Methods

ISSN: 0166-0934

DAY: 19

MONTH: 11

YEAR: 2007

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8005839

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Development and application of monoclonal antibodies against avian influenza virus nucleoprotein.

AFFILIATION: National Centre for Foreign Animal Disease, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3M4.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Virol Methods

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Development and application of monoclonal antibodies against avian influenza virus nucleoprotein Related Publications

• Development and application of monoclonal antibodies against avian influenza virus nucleoprotein.
• Production of monoclonal antibodies against whole virus particles of foot-and-mouth disease virus serotype O and A and their potential use in quantification of intact virus for vaccine manufacture.
• Use of a standardized bovine serum panel to evaluate a multiplexed nonstructural protein antibody assay for serological surveillance of foot-and-mouth disease.
• [Trypanosoma rangeli parasite-vector-vertebrate interactions and their relationship to the systematics and epidemiology of American trypanosomiasis]